이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Effect of Stellate Ganglion Block on Sleep Quality in Patients With Depression

2026년 10월 8일 업데이트: Li Juan

# Brief Summary

This clinical research study looks at whether stellate ganglion block (SGB) can improve sleep quality for people with depression. Poor sleep often goes together with depression. Medicines used for these conditions may cause side-effects or dependency. Researchers want to learn if SGB, a minimally-invasive nerve treatment, can help sleep and mood without those medicine-related downsides.

This study uses a self-controlled design. Every person who joins will receive the study treatment. No separate comparison group is enrolled. Researchers will collect sleep data from each participant before treatment and again after treatment, then compare these two sets of information.

About 42 participants will take part in this study.

Key requirements to join the study:

  • Aged 18 to 65 years old
  • Have depression-related symptoms and sleep trouble
  • Able to understand and sign an informed consent form
  • No medical conditions that make SGB unsafe
  • Have not taken sleep-affecting medicines or received other sleep-focused treatments in the past one month
  • Can follow study schedules and complete all study assessments

People cannot join if they:

  • Are younger than 18 years or older than 65 years
  • Are pregnant or breastfeeding
  • Have known allergies to study-used medicines
  • Have unstable serious organ diseases, uncontrolled substance or alcohol dependence
  • Cannot keep fixed daily routines or finish all study visits

Study procedures for each participant:

  1. On study day zero (D0): Study staff will explain the study fully. Participants will sign informed consent. Staff will run physical checks and blood tests. Participants will fill out several simple questionnaires about mood and sleep. Sleep will be measured overnight with a multi-channel sleep recording device called polysomnography (PSG). Participants also keep a short sleep diary.
  2. From study day one (D1) to day five (D5): Participants get one SGB treatment each day, for a total of five treatments. During SGB, a doctor uses ultrasound guidance to inject small-dose local anesthetic near nerves in the neck. Participants keep completing their sleep diary every day. Study staff watch for any unwanted reactions during each treatment.
  3. On the night of D5 through early morning of D6: PSG sleep recording will be repeated after the final SGB treatment.
  4. On study day six (D6): Participants finish the final set of mood-and-sleep questionnaires. Study staff collect all safety information.

Researchers will compare sleep measurements taken before treatment versus after five-day SGB treatment. Collected data includes objective sleep readings from PSG and self-reported sleep information from sleep diaries. Questionnaires will show changes in depression and insomnia symptoms.

Possible benefits: SGB may make participants' sleep better and may ease depression-related symptoms. No benefit is guaranteed for every participant.

Possible risks: SGB is generally safe. Rare unwanted reactions may include temporary hoarseness, local neck-site infection, or drug allergic responses. Study doctors will watch participants closely. If serious problems happen, immediate medical help will be provided.

All participants' private personal information will be protected. Participants can choose to stop taking part in this research at any time without penalty.

연구 개요

상태

아직 모집하지 않음

연구 유형

중재적

등록 (추정된)

42

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Aged 18-65 years of both genders. Alert and capable of normal communication. Voluntarily sign informed consent, complete the whole experimental procedure, and meet ethical and compliance requirements.
  2. Hamilton Depression Rating Scale (HAMD) score ≥ 8.
  3. Insomnia Severity Index (ISI) score ≥ 7 or Pittsburgh Sleep Quality Index (PSQI) score ≥ 7.
  4. No contraindications to stellate ganglion block (SGB); no cervical deformity, trauma, or infection; and no severe cervical spine disease, such as cervical fracture or cervical disc herniation with nerve compression.
  5. No use of sedative-hypnotics, anxiolytics, antidepressants, or other medications that may affect sleep within the past month, and no acupuncture, massage, nerve block, or other sleep-related interventions during the same period.
  6. Stable vital signs; normal liver and renal function, complete blood count, and coagulation function; and no severe organic diseases of the heart, brain, lungs, liver, or kidneys.
  7. Able to strictly follow the required sleep-wake schedule and cooperate with polysomnography (PSG) monitoring and completion of sleep diaries, with good study compliance.

Exclusion Criteria:

  • 1: Age <18 or >65 years; pregnant or lactating women; subjects with psychiatric disorders (schizophrenia, mania, etc.) or cognitive impairment who cannot cooperate with the study, to prevent missing data and experimental bias.

    2: Presence of contraindications to stellate ganglion block, such as coagulation disorders, local skin infection, severe cervical spine disease, hyperthyroidism, glaucoma, or increased intracranial pressure.

    3: Allergy to ropivacaine, epinephrine, or other drugs used for the block, or a history of drug allergy.

    4: Use of sedative-hypnotics, anxiolytics, antidepressants, hormonal medications, or other treatments that may affect sleep within the past month.

    5: Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, hematologic disease, respiratory disease, or other serious organic diseases, or a recent history of surgery or trauma.

    6: Alcohol dependence or drug dependence, or daily consumption of coffee, strong tea, or other stimulating beverages with inability to abstain during the study period.

    7: Inability to maintain a fixed sleep-wake schedule during the study or inability to complete the full monitoring and intervention procedures because of work, daily life, or other reasons.

    8: Voluntary withdrawal during the study, or inability to complete the study because of adverse reactions, poor compliance, or other reasons.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SGB group

Stellate Ganglion Block

Using an anterior-lateral approach, participants lie supine with head turned contralaterally to expose the neck. The interspace between the anterior sternocleidomastoid border, trachea and common carotid artery is identified. Skin is disinfected 3 times with iodophor (≥15 cm diameter), then covered with a sterile aperture drape.

A 22-G needle is inserted vertically at the target site. After bony contact with the C6 transverse process, the needle is retracted 0.1-0.2 cm. With negative aspiration for blood and cerebrospinal fluid, inject 6 mL 0.25% ropivacaine (epinephrine 1:200 000) at 1 mL/min to limit bleeding and prolong block effect.

Monitor blood pressure, heart rate, oxygen saturation, and adverse events (hoarseness, Horner syndrome, dyspnea) throughout injection.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Sleep Onset Latency, SOL
기간: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Wake After Sleep Onset, WASO
기간: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Total Sleep Time, TST
기간: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Proportions of each non-rapid eye movement sleep stage
기간: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Proportions of REM, NREM and Wake
기간: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
Sleep Efficiency, SE
기간: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
At baseline (Day 0) and from Night 5 to Morning 6 after intervention

2차 결과 측정

결과 측정
기간
Subjective sleep-onset latency
기간: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Subjective Total Sleep Time
기간: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Subjective Sleep Efficiency
기간: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning
Sleep Satisfaction
기간: 30 minutes after awakening on the corresponding next morning
30 minutes after awakening on the corresponding next morning

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 20일

기본 완료 (추정된)

2026년 12월 1일

연구 완료 (추정된)

2026년 12월 30일

연구 등록 날짜

최초 제출

2026년 9월 7일

QC 기준을 충족하는 최초 제출

2026년 9월 17일

처음 게시됨 (실제)

2026년 9월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 8일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • BoYi Medical Ethics No.1162026

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data underlying the published results will be available to qualified researchers after article publication. Data access requires a formal research proposal and signed data-use agreement.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다